Total Payments
$18,286
2024 Payments
$1,371
Companies
14
Transactions
39
Medicare Patients
12,692
Medicare Billing
$13.9M
Payment Breakdown by Category
Other$14,432 (78.9%)
Travel$1,472 (8.0%)
Food & Beverage$1,383 (7.6%)
Consulting$1,000 (5.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $8,315 | 1 | 45.5% |
| Current or prospective ownership or investment interest | $5,992 | 6 | 32.8% |
| Travel and Lodging | $1,472 | 4 | 8.0% |
| Food and Beverage | $1,383 | 20 | 7.6% |
| Consulting Fee | $1,000 | 1 | 5.5% |
| Honoraria | $125.00 | 1 | 0.7% |
| Unspecified | $0 | 6 | 0.0% |
Payments by Type
General
$18,286
33 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Retina LLC | $14,307 | 13 | $0 (2022) |
| Dutch Ophthalmic, USA | $2,377 | 4 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $474.38 | 6 | $0 (2019) |
| Ocular Therapeutix, Inc. | $197.60 | 2 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $146.87 | 2 | $0 (2019) |
| Astellas Pharma US Inc | $128.24 | 2 | $0 (2024) |
| Welch Allyn | $125.00 | 1 | $0 (2018) |
| Genentech USA, Inc. | $114.22 | 2 | $0 (2019) |
| Alcon Vision LLC | $111.18 | 1 | $0 (2022) |
| AbbVie, Inc. | $99.85 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,371 | 3 | Dutch Ophthalmic, USA ($1,338) |
| 2023 | $1,095 | 2 | Dutch Ophthalmic, USA ($1,000) |
| 2022 | $10,866 | 7 | US Retina LLC ($10,638) |
| 2021 | $2,000 | 3 | US Retina LLC ($2,000) |
| 2020 | $722.44 | 2 | US Retina LLC ($722.44) |
| 2019 | $1,380 | 9 | US Retina LLC ($947.25) |
| 2018 | $852.84 | 12 | Novartis Pharmaceuticals Corporation ($352.63) |
| 2017 | $0 | 1 | US Retina LLC |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/16/2024 | Dutch Ophthalmic, USA | EVA, combined machine (Device), TISSUEBLUE | Travel and Lodging | In-kind items and services | $1,273.52 | General |
| Category: Ophthalmology | ||||||
| 09/23/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $33.70 | General |
| Category: Ophthalmology | ||||||
| 02/07/2024 | Dutch Ophthalmic, USA | EVA, combined machine (Device), TISSUEBLUE | Food and Beverage | In-kind items and services | $64.27 | General |
| Category: Ophthalmology | ||||||
| 08/28/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $94.54 | General |
| 02/03/2023 | Dutch Ophthalmic, USA | EVA, combined machine (Device), TISSUEBLUE | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Ophthalmology | ||||||
| 12/01/2022 | US Retina LLC | — | Acquisitions | Cash or cash equivalent | $8,314.50 | General |
| 08/11/2022 | Alcon Vision LLC | Clareon (Device) | Food and Beverage | In-kind items and services | $111.18 | General |
| Category: Ophthalmology | ||||||
| 08/03/2022 | Dutch Ophthalmic, USA | EVA, combined machine (Device) | Food and Beverage | In-kind items and services | $39.43 | General |
| Category: Ophthalmology | ||||||
| 04/13/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $2,020.28 | General |
| 04/12/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $303.00 | General |
| 02/18/2022 | TearLab Corp | TEARLAB OSMOLARITY SYSTEM (Device) | Food and Beverage | In-kind items and services | $77.22 | General |
| Category: DIAGNOSTICS | ||||||
| 2022 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 05/11/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $1,736.18 | General |
| 05/06/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $263.32 | General |
| 2021 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 03/13/2020 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $722.44 | General |
| 2020 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 10/11/2019 | Novartis Pharmaceuticals Corporation | BUPARLISIB (Drug) | Food and Beverage | In-kind items and services | $121.75 | General |
| 10/11/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $58.71 | General |
| Category: None | ||||||
| 10/11/2019 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/13/2019 | Ocular Therapeutix, Inc. | ReSure Sealant (Device), DEXTENZA, DEXTENZA | Food and Beverage | In-kind items and services | $98.80 | General |
| Category: Ophthalmology | ||||||
| 06/13/2019 | Ocular Therapeutix, Inc. | DEXTENZA (Drug), DEXTENZA, DEXTENZA | Food and Beverage | In-kind items and services | $98.80 | General |
| Category: Ophthalmology | ||||||
| 02/27/2019 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: RETINA | ||||||
| 02/21/2019 | US Retina LLC | — | Current or prospective ownership or investment interest | Stock option | $947.25 | General |
| 01/24/2019 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 2,855 | 20,829 | $7.3M | $3.5M |
| 2022 | 22 | 2,964 | 13,083 | $6.7M | $3.3M |
| 2021 | 23 | 3,578 | 11,835 | $7.3M | $3.6M |
| 2020 | 17 | 3,295 | 11,283 | $6.8M | $3.4M |
Total Patients
12,692
Total Services
57,030
Medicare Billing
$13.9M
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 303 | 3,782 | $5.0M | $2.6M | 51.6% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 21 | 9,180 | $451,381 | $267,425 | 59.2% |
| 67028 | Injection of drug into eye | Office | 2023 | 365 | 2,030 | $628,100 | $178,604 | 28.4% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 33 | 960 | $166,397 | $115,546 | 69.4% |
| 92134 | Imaging of retina | Office | 2023 | 839 | 2,988 | $242,028 | $87,489 | 36.1% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 15 | 373 | $201,400 | $66,520 | 33.0% |
| J3490 | Unclassified drugs | Office | 2023 | 18 | 28 | $72,800 | $49,517 | 68.0% |
| J3590 | Unclassified biologics | Office | 2023 | 15 | 23 | $59,800 | $40,936 | 68.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 349 | 423 | $104,058 | $37,557 | 36.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 296 | 391 | $81,719 | $35,409 | 43.3% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 20 | 20 | $54,000 | $17,635 | 32.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 146 | 191 | $27,122 | $11,934 | 44.0% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 105 | 105 | $30,975 | $10,892 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 90 | 90 | $28,710 | $10,756 | 37.5% |
| 67039 | Destruction of eye fluid (vitreous) between lens and retina using a laser | Facility | 2023 | 14 | 14 | $27,930 | $10,268 | 36.8% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 16 | 16 | $28,272 | $9,351 | 33.1% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 87 | 87 | $17,400 | $8,818 | 50.7% |
| 92250 | Photography of the retina | Office | 2023 | 82 | 86 | $10,578 | $2,354 | 22.2% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Facility | 2023 | 12 | 12 | $12,420 | $1,002 | 8.1% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 17 | 18 | $3,800 | $689.09 | 18.1% |
| 92285 | Photography of content of eyes | Office | 2023 | 12 | 12 | $840.00 | $213.84 | 25.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 310 | 3,642 | $4.8M | $2.6M | 53.7% |
| 67028 | Injection of drug into eye | Office | 2022 | 343 | 1,902 | $580,525 | $165,733 | 28.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 22 | 570 | $309,400 | $127,083 | 41.1% |
| J3590 | Unclassified biologics | Office | 2022 | 15 | 52 | $136,600 | $93,759 | 68.6% |
About Dr. Jamin Brown, M.D
Dr. Jamin Brown, M.D is a Ophthalmology healthcare provider based in Liverpool, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235242124.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jamin Brown, M.D has received a total of $18,286 in payments from pharmaceutical and medical device companies, with $1,371 received in 2024. These payments were reported across 39 transactions from 14 companies. The most common payment nature is "Acquisitions" ($8,315).
As a Medicare-enrolled provider, Brown has provided services to 12,692 Medicare beneficiaries, totaling 57,030 services with total Medicare billing of $13.9M. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Retina Specialist
- Location Liverpool, NY
- Active Since 08/16/2006
- Last Updated 08/24/2020
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1235242124
Products in Payments
- EVA, combined machine (Device) $2,377
- EYLEA AFLIBERCEPT INJECTION (Biological) $125.00
- RetinaVue Network (Device) $125.00
- BUPARLISIB (Drug) $121.75
- Lucentis (Biological) $114.22
- Clareon (Device) $111.18
- Humira (Biological) $99.85
- DEXTENZA (Drug) $98.80
- ReSure Sealant (Device) $98.80
- TEARLAB OSMOLARITY SYSTEM (Device) $77.22
- Non-Covered Product (Drug) $58.71
- OZURDEX (Drug) $41.96
- Izervay (Drug) $33.70
- EYLEA (Biological) $21.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Liverpool
Dr. Justin Dexter, Md, MD
Ophthalmology — Payments: $55,394
Ophthalmology $55,394
Dr. Kevin Rosenberg, Md, MD
Ophthalmology — Payments: $15,491
Ophthalmology $15,491
Rajeev Seth, Md, MD
Ophthalmology — Payments: $14,771
Ophthalmology $14,771
Samuel Spalding, M.d, M.D
Ophthalmology — Payments: $14,718
Ophthalmology $14,718
Marc Safran, M.d, M.D
Ophthalmology — Payments: $4,076
Ophthalmology $4,076
Dr. Leslie Woodcock, M.d, M.D
Ophthalmology — Payments: $3,495
Ophthalmology $3,495